ONCOLOGY NURSING SOCIETY
BOARD OF DIRECTORS
APPROVED MINUTES

Date: Tuesday, April 18, 2017
Time: 6:00 pm – 8:00 pm EST
Place: conference call

Attendees: President, Susan Schneider; Secretary, Barbara Holmes Gobel; Treasurer, Kay Harse; Directors-at-Large, Donald Bailey, Eva Gallagher, Diane Barber, Joni Watson, Colleen O’Leary, Jean Rosiak; Chief Executive Officer, Brenda Nevidjon

Absent: none

Guests: Chief Strategy Officer, M. McCorkle; Chief Clinical Officer, L. Kennedy Sheldon; Chief Experience Officer, L. Brown; Executive Director of ONS Foundation, L. Worrall; Assistant Chief Clinical Officer, M. Galioto

Recorder(s): Jennifer DiVito, Senior Executive Assistant

I. **Call to Order**
   S. Schneider called the meeting to order at 6:01 pm EST.

II. **Introduction**
   L. Brown, Chief Experience Officer, was introduced to the ONS Board. Lori brings 18 years of combined marketing experience in retail, customer relations, and the healthcare industry. She has an MBA from Point Park University and has spent the last 10 years at Highmark Health in Consumer Experience and Customer Centricity, prior to that she was with DelMonte Foods as Brand Manager of Strategic Innovation

III. **Assignment of To-Do List and Timekeeper**
   E. Gallagher has been assigned to capture the to-do list and D. Bailey will be the timekeeper.

IV. **Approval of Agenda including consent agenda and timeframes**
   J. Rosiak moved to approve the agenda including the consent agenda and timeframes as submitted. The motion was adopted.
V. **Conflict of Interest**
B. Gobel disclosed that she is currently working on an addendum to *Cancer Nursing Principles and Practice* book and has not reviewed the materials related to the ONCC blueprint.

VI. **Need for an executive session**
No need for an executive session

VII. **E-mail Vote** – The March meeting minutes were approved via email vote on April 14, 2017.

VIII. **Presidents Update**
S. Schneider reviewed the May Board meeting agenda topics with the returning Board members and reviewed the Board Buddy assignments, which matches a returning Board member with an incoming Board member. The ONS Board has decided that the next joint meeting with the Leadership Development Committee will be scheduled during Leadership Weekend.

IX. **Gift Policy**
B. Gobel moved to approve the addition of Section H to the Conflict of Interest Policy to read as follows:
An individual may not accept gifts beyond nominal value from vendors, potential vendors, customers, contractors, consultants, sponsors or potential sponsors, or where the receipt of the gift may create an appearance of a conflict. Cash gifts may never be accepted regardless of value.

Nominal value is considered $100 or less per gift. The cumulative value any individual may receive from a single provider is $250 annually.

Gifts received with a value between $100 and $400 may be accepted provided they are gifts to ONS and not to an individual. Such organization gifts may be raffled off or dispersed in a similar manner.

Complimentary or reduced fee travel, registration and related costs for trips to vendor or sponsor operations, user conferences or similar events
conducted as part of the due diligence in researching options, evaluating products and services, and learning opportunities are not considered gifts.

The motion was adopted.

X. ONS Foundation Trustee Nominations

L. Worrall presented the candidates identified as future Trustees to the Board and the recommendation for the next President to the ONS Board of Directors. D. Bailey moved to appoint C. LeBlanc as the President of the ONS Foundation for term of one year beginning on June 1st with the opportunity for an additional year. The motion was adopted.

C. O’Leary moved to approve the appointment of M. Dodd, T. Gosselin, J. Poister and D. Whalen to the ONS Foundation Board effective June 1st for a maximum of three years. The motion was adopted.

XI. IO Think Tank Summary

The Immuno-Oncology Think Tank was convened by the Oncology Nursing Society (ONS) in Pittsburgh, PA, on March 28, 2017 to:

1. Assess the current issues related to the care of patients receiving immuno-oncology (I-O) therapies.

2. Identify priority issues (from the attendee perspective) and gaps in knowledge, skill and practice to assist in setting ONS priorities and provide guidance on adjustments of current and the creation of new ONS products about I-O therapies.

3. Recommend strategies to the ONS Board for developing resources and training for ONS members working with immuno-oncology agents.

XII. IO Knowledge Institute

The I-O KI will provide a framework to support ONS strategic and core goals related to providing safe, quality care for patients receiving immuno-oncology agents. The I-O KI work will facilitate practice-based evidence for the administration of and care of those individuals receiving I-O agents.

I-O KI work spans over 5 years to allow for optimal reporting on data analysis and recommendations and proposes the following outcomes:
• Developing standards of care for handling, administration and care for those receiving I-O agents, collaboratively with other organizations as appropriate
• Developing triage resources for standards implementation for use in priority treatment areas along the I-O care trajectory (oncology care, emergency department, primary care)
• Developing, testing and deploying quality measures to provide real-time evaluation of patient outcomes related to provision of care; measures will be applicable in multiple care settings (oncology, ED, primary care)
• Providing education to support understanding of and integration of IO-related evidence and best practice into competency development and assessment for administration of and patient education for I-O agents; includes production of patient education resources
• Developing tools to integrate I-O into shared decision making models, advocating for optimal treatment and patient outcomes
• Leading and supporting patient-centered research for optimal irAE prevention and management, which may include data analysis of de-identified patient data obtained from oncology data lakes and registries, with the intent of defining assessment strategies and gaps in meeting optimal patient outcomes
• Monitoring de-identified staff health data for those administering and caring for those receiving I-O agents to improve understanding of safe handling requirements for I-O therapies, collaborating with other entities as appropriate
• Monitoring legislative and policy environments that impact quality patient care and direct access to the I-O agents

J. Rosiak moved to approve staff moving forward with development of Immune-Oncology Knowledge Institute as outlined. The motion was adopted. The ONS Board approved the allocation of $725K for the development of the Institute over a 2 year period. The CFO, CEO and Treasurer will look at existing budget monies for the funding; whether we can obtain sponsorship, or whether we need to utilize some of our investment funds for this initiative.

XIII. Research Think Tank Summary
ONS and the ONS Foundation conducted a Research Think Tank in Pittsburgh, March 20-21st bringing in oncology nursing research experts from across the country. Based on the Research Think Tank outcomes, ONS will identify its top three research priorities. These foci will help the ONS Foundation form support campaigns. In addition, ONS will also create a marketing strategy to propel the evidence from oncology nursing research into major media outlets, such as the Washington Post and the New York Times, and highlight how oncology nurse research impacts practice and patient outcomes.

XIV. **Best Practice Exchange**
The ONS Board discussed the purpose for the Best Practice Exchange and reviewed potential questions to ask the attendees related to challenges faced in their respective practice. The Best Practice Exchange also provides a platform to discuss trends that may affect nurses and their patients in the future. The ONS Board President and CEO will be in attendance for both sessions scheduled during Congress. The following Board members will attend one of the two sessions scheduled.

**Thursday, May 4th (1:45-2:45pm)**
- D. Bailey
- B. Gobel
- K. Harse
- J. Rosiak

**Friday, May 5th (1:45-2:45 pm)**
- J. Watson
- C. O’Leary
- D. Barber
- E. Gallagher

XV. **CEO Update**
The CEO provided an overview of the ONS approver unit financials over the last two years. In addition, the status of the ONS/ONCC contract was discussed.

XVI. **Adjournment**
S. Schneider adjourned the meeting at 8:10 pm EST.